The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

AstraZeneca said it entered into a strategic research collaboration with China's CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

Researchers from King's College London have called for urgent changes to the way new antibiotics are developed to address the ...

Rep Kim Schrier, MD, (D-Wash.), said on X yesterday that some of the newly appointed ACIP replacements are anti-vaccine ...

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting ...

PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and market headwinds.

The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting -- loss of relevancy" says Susan Galbraith, EVP of Oncology R&D at AstraZeneca.

WASHINGTON — Health secretary Robert F. Kennedy Jr. on Wednesday unveiled the names of the eight new members who will sit on ...

Investigational efimosfermin alfa was safe and well tolerated among patients with phenotypic metabolic dysfunction-associated ...